BidaskClub upgraded shares of Luminex (NASDAQ:LMNX) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday.

Several other equities analysts also recently weighed in on LMNX. ValuEngine upgraded Luminex from a hold rating to a buy rating in a research report on Tuesday, April 17th. William Blair reiterated a market perform rating on shares of Luminex in a research report on Tuesday, February 13th. Finally, BTIG Research assumed coverage on Luminex in a research report on Friday, January 5th. They set a buy rating and a $24.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $22.33.

NASDAQ LMNX opened at $22.20 on Thursday. Luminex has a twelve month low of $18.22 and a twelve month high of $22.59. The stock has a market cap of $986.37, a P/E ratio of 26.75, a price-to-earnings-growth ratio of 2.09 and a beta of 0.11.

Luminex (NASDAQ:LMNX) last released its earnings results on Monday, February 12th. The medical instruments supplier reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.11. Luminex had a return on equity of 8.48% and a net margin of 9.48%. The firm had revenue of $78.20 million for the quarter, compared to the consensus estimate of $77.33 million. During the same period in the prior year, the business posted $0.11 earnings per share. The firm’s revenue for the quarter was up 8.2% compared to the same quarter last year. analysts predict that Luminex will post 0.66 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 13th. Stockholders of record on Friday, March 23rd were issued a $0.06 dividend. The ex-dividend date was Thursday, March 22nd. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.08%. Luminex’s dividend payout ratio (DPR) is 26.37%.

Institutional investors have recently added to or reduced their stakes in the company. Creative Planning purchased a new position in shares of Luminex in the 4th quarter worth about $198,000. UBS Asset Management Americas Inc. purchased a new position in shares of Luminex in the 4th quarter worth about $206,000. Teacher Retirement System of Texas purchased a new position in shares of Luminex in the 4th quarter worth about $270,000. Waldron LP purchased a new position in shares of Luminex in the 4th quarter worth about $330,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Luminex in the 4th quarter worth about $372,000. Institutional investors own 80.75% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with's FREE daily email newsletter.